This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Williams, D. O. Search for Related Content PubMed PubMed Citation Articles by Williams, D. O. Related Collections Restenosis Catheter-based coronary and valvular interventions: other Catheter-based coronary interventions: stents

(Circulation. 2002;105:2699.)
© 2002 American Heart Association, Inc.

Intracoronary Brachytherapy

Past, Present, and Future

David O. Williams, MD

From the Division of Cardiology, Department of Medicine, Brown University School of Medicine, Rhode Island Hospital, Providence, RI.

Correspondence to David O. Williams, MD, APC 814, Rhode Island Hospital, 593 Eddy St, Providence, RI 02903. E-mail dowilliams@lifespan.org

Key Words: Editorials • restenosis • brachytherapy • angioplasty • stents

The purpose of intracoronary brachytherapy is to reduce the incidence of lesion recurrence (restenosis) after percutaneous coronary intervention. Its rationale is based on the concept that restenosis is a process of benign tissue proliferation and that locally applied radiation can prevent or attenuate the magnitude of this response. After encouraging results from animal models,^1,2 small observational and randomized clinical trials were initiated to demonstrate the feasibility and safety of this unique application of radiation.^3–5 Positive findings led to larger randomized trials that demonstrated a powerful treatment effect.^6,7 In patients presenting with restenosis within a previously implanted stent, the likelihood of repeat restenosis was reduced by 50%. Results of brachytherapy administered to patients undergoing balloon angioplasty alone or at the time of stent implantation have been inconsistent. At this time, brachytherapy is considered to be a standard treatment alternative for selected patients with in-stent restenosis, and it is performed as a component of routine practice in interventional cardiology.

See p 2737

Several questions remain unanswered, however, about intracoronary brachytherapy. In particular, does this treatment delay or prevent restenosis? Can it stimulate atherosclerosis elsewhere in the coronary circulation? Does it create the potential for spontaneous coronary rupture or thrombosis? Are there any untoward extra-coronary effects, such as myocardial or pericardial fibrosis?

In this issue of Circulation, Grise and colleagues⁸ provide information to help answer these questions. They report the 5-year clinical outcomes of 55 patients enrolled in the first randomized trial comparing ¹⁹²Ir to a nonradioactive control. Each patient in this . . . [Full Text of this Article]

This article has been cited by other articles:

				D. E. Kandzari and D. B. Mark Intracoronary Brachytherapy: Time to Sell Short? Circulation, August 6, 2002; 106(6): 646 - 648. [Full Text] [PDF]